Anzeige
Mehr »
Samstag, 19.07.2025 - Börsentäglich über 12.000 News
Kupfer en mass...: 10 Prozent-Kupfer an der Oberfläche! - Diese Entdeckung könnte zur heißesten Kupferstory des Jahres werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JKQ4 | ISIN: CA29668H7085 | Ticker-Symbol:
NASDAQ
18.07.25 | 15:39
1,865 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ESSA PHARMA INC Chart 1 Jahr
5-Tage-Chart
ESSA PHARMA INC 5-Tage-Chart

Aktuelle News zur ESSA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoESSA Pharma to be acquired by XenoTherapeutics in all-cash deal3
MoESSA Pharma Inc. - 8-K, Current Report5
MoESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction165SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:...
► Artikel lesen
08.05.ESSA Pharma GAAP EPS of -$0.141
ESSA PHARMA Aktie jetzt für 0€ handeln
08.05.ESSA Pharma Inc. - 8-K, Current Report1
08.05.ESSA Pharma Inc. - 10-Q, Quarterly Report5
08.05.ESSA Pharma Inc: ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025106Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 ...
► Artikel lesen
06.03.Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders204SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company...
► Artikel lesen
06.03.ESSA Pharma Inc. - 8-K, Current Report-
11.02.ESSA Pharma GAAP EPS of -$0.19 misses by $0.011
11.02.ESSA Pharma Inc: ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024171Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb....
► Artikel lesen
11.02.ESSA Pharma Inc. - 8-K, Current Report-
11.02.ESSA Pharma Inc. - 10-Q, Quarterly Report-
17.12.24ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024190Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER...
► Artikel lesen
12.11.24ESSA Pharma: NBC-Anlegerclub feiert schnelle +23% Rendite!438Der No Brainer Club (NBC) hat erneut sein Gespür für unterbewertete Biotech-Perlen unter Beweis gestellt. Mit ESSA Pharma konnten Mitglieder in diesem fulminanten Biotech-Herbst innerhalb weniger Tage...
► Artikel lesen
01.11.24Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma1.232CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15. VS...
► Artikel lesen
01.11.24ESSA Pharma Inc: ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer174Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation...
► Artikel lesen
13.09.24ESSA Pharma Inc: ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress1.048Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten...
► Artikel lesen
05.08.24ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024172On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1